Contineum CEO trades shares via 10b5-1 plan

Contineum Therapeutics CEO Carmine N. Stengone reported option exercises and share sales in Contineum Therapeutics, Inc. He exercised stock options for 7,100 shares of Class A common stock at an exercise price of $1.26 per share on February 24 and 25, 2026.

Rhea-AI Filing Summary

Contineum Therapeutics CEO Carmine N. Stengone reported option exercises and share sales in Contineum Therapeutics, Inc. He exercised stock options for 7,100 shares of Class A common stock at an exercise price of $1.26 per share on February 24 and 25, 2026. On the same dates, he sold a total of 7,100 Class A common shares in open-market transactions at weighted average prices of $16.0195 and $16.0155 per share, with actual prices ranging from $16.00 to $16.15. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on September 23, 2025. After these transactions, he held 14,954 shares of Class A common stock and 120,917 stock options directly.

Insider Trade Summary

Exercise and Sale: 7,100 shares ($105K approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Stengone Carmine N.

Role CEO and President

Sold 7,100 shs ($114K)

Approx. gross sale proceeds $114K

Approx. exercise cost $9K

Approx. pre-tax spread $105K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	2,700	$0.00	$0.00
Exercise	Class A Common Stock	2,700	$1.26	$3K
Sale	Class A Common Stock	2,700	$16.0155	$43K
Exercise	Stock Option (right to buy)	4,400	$0.00	$0.00
Exercise	Class A Common Stock	4,400	$1.26	$6K
Sale	Class A Common Stock	4,400	$16.0195	$70K

Holdings After Transaction: Stock Option (right to buy) — 120,917 contracts (Direct); Class A Common Stock — 14,954 shares (Direct)

Footnotes (4)

1. F1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.15, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.05, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
4. F4. The stock options are fully vested and exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Contineum Therapeutics (CTNM) CEO Carmine Stengone report on this Form 4?

Carmine N. Stengone reported exercising stock options and selling Contineum Therapeutics Class A common shares. The filing shows option exercises for 7,100 shares and open-market sales of 7,100 shares over two days in February 2026.

How many Contineum Therapeutics (CTNM) shares did the CEO sell and at what prices?

The CEO sold 7,100 Class A common shares in total. Weighted average sale prices were about $16.0195 and $16.0155 per share, with individual trades ranging from $16.00 to $16.15 per share, as detailed in the Form 4 footnotes.

What stock option activity did the CTNM CEO report in this Form 4?

He reported exercising stock options for 7,100 shares of Class A common stock. The options were exercised at an exercise price of $1.26 per share and are described as fully vested and exercisable according to a footnote in the filing.

Were the CTNM CEO’s trades made under a Rule 10b5-1 trading plan?

Yes. A footnote states these transactions were effected pursuant to a Rule 10b5-1 trading plan. The plan was adopted by the reporting person on September 23, 2025, and governed the reported February 2026 trades.

How many Contineum Therapeutics (CTNM) shares does the CEO hold after these transactions?

After the reported transactions, the CEO directly holds 14,954 shares of Class A common stock. He also directly holds 120,917 stock options described as fully vested and exercisable, based on the share balances shown following the transactions.

What types of transactions are reflected in this Contineum Therapeutics (CTNM) Form 4?

The Form 4 shows derivative exercises and open-market sales. It records multiple “M” code transactions for exercising stock options into Class A common shares, and “S” code transactions reflecting open-market or private sales of those Class A common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/26/2026 - 04:40 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stengone Carmine N.

(Last) (First) (Middle)

3565 GENERAL ATOMICS COURT, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Contineum Therapeutics, Inc. [ CTNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/24/2026		M(1)		4,400	A	$1.26	19,354	D
Class A Common Stock	02/24/2026		S(1)		4,400	D	$16.0195(2)	14,954	D
Class A Common Stock	02/25/2026		M(1)		2,700	A	$1.26	17,654	D
Class A Common Stock	02/25/2026		S(1)		2,700	D	$16.0155(3)	14,954	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.26	02/24/2026		M(1)			4,400	(4)	11/13/2028	Class A Common Stock	4,400	$0	123,617	D
Stock Option (right to buy)	$1.26	02/25/2026		M(1)			2,700	(4)	11/13/2028	Class A Common Stock	2,700	$0	120,917	D

Explanation of Responses:

1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.15, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.05, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

4. The stock options are fully vested and exercisable.

	/s/ Peter Slover, Attorney-in-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.